SG Biomedical specializes in innovative plasma medical technology, pioneering the use of plasma treatment for chronic wounds in surgical care. With over 18 years of clinical evidence from hospitals in Germany, the UK, and the European Union, its efficacy has been validated by more than 82 professional medical journals worldwide. The technology is applicable to various types of wound care, including acute and chronic large wounds, diabetic foot ulcers, surgical wound infections, and burn infections.

Since 2023, SG Biomedical has been expanding its plasma medical device business across Asia, establishing presence in Taiwan’s top ten medical centers. The company plans to extend its reach to over 30 medical centers nationwide by 2026. In parallel, it is actively developing markets in six Southeast Asian countries, Japan, Australia, Mainland China, Hong Kong, and other key Asian regions—totaling twelve strategic medical markets—and aims to establish Taiwan as a manufacturing hub for plasma medical devices.

In June 2025, SG Biomedical formed a strategic alliance with a major U.S. biotech fund to jointly invest in UK-based Edit Medical, acquiring over 65% ownership. This equity partnership integrates enterprises from Taiwan, the UK, and the U.S., collaboratively driving FDA certification for the U.S. market while deepening market development in Europe and Asia. The alliance envisions capturing the vast global plasma medical market.

SG Biomedical’s plasma medical products feature low temperature operation, no side effects, safety, painless and contactless treatment, short treatment times, consistent efficacy, and cost competitiveness. Extensive clinical evidence accumulated in the EU and Taiwan’s medical centers demonstrates positive impacts on acute and chronic wound patients, including reducing amputation risk, decreasing hospitalization frequency, lowering antibiotic usage, and minimizing surgical interventions. This multinational equity alliance will continue to lead the global expansion of innovative plasma medical products, establishing a synergistic operational model across Taiwan, the UK, and the U.S., and creating worldwide commercial opportunities in plasma medicine.

Resource: 施吉生技佈局創新電漿醫療 再創醫療產業里程碑